Cargando…

Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment

In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Huanhuan, Li, Siyi, Zhong, Xin, Huang, Shuxuan, Jiao, Xue, He, Guoyong, Jiang, Bingjian, Liu, Yuping, Gao, Zhili, Wei, Jinhong, Lin, Yushen, Chen, Zhi, Li, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487126/
https://www.ncbi.nlm.nih.gov/pubmed/36127663
http://dx.doi.org/10.1186/s12883-022-02898-6
_version_ 1784792426965106688
author Lu, Huanhuan
Li, Siyi
Zhong, Xin
Huang, Shuxuan
Jiao, Xue
He, Guoyong
Jiang, Bingjian
Liu, Yuping
Gao, Zhili
Wei, Jinhong
Lin, Yushen
Chen, Zhi
Li, Yanhua
author_facet Lu, Huanhuan
Li, Siyi
Zhong, Xin
Huang, Shuxuan
Jiao, Xue
He, Guoyong
Jiang, Bingjian
Liu, Yuping
Gao, Zhili
Wei, Jinhong
Lin, Yushen
Chen, Zhi
Li, Yanhua
author_sort Lu, Huanhuan
collection PubMed
description In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
format Online
Article
Text
id pubmed-9487126
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94871262022-09-21 Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment Lu, Huanhuan Li, Siyi Zhong, Xin Huang, Shuxuan Jiao, Xue He, Guoyong Jiang, Bingjian Liu, Yuping Gao, Zhili Wei, Jinhong Lin, Yushen Chen, Zhi Li, Yanhua BMC Neurol Research In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. BioMed Central 2022-09-20 /pmc/articles/PMC9487126/ /pubmed/36127663 http://dx.doi.org/10.1186/s12883-022-02898-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lu, Huanhuan
Li, Siyi
Zhong, Xin
Huang, Shuxuan
Jiao, Xue
He, Guoyong
Jiang, Bingjian
Liu, Yuping
Gao, Zhili
Wei, Jinhong
Lin, Yushen
Chen, Zhi
Li, Yanhua
Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
title Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
title_full Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
title_fullStr Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
title_full_unstemmed Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
title_short Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
title_sort immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487126/
https://www.ncbi.nlm.nih.gov/pubmed/36127663
http://dx.doi.org/10.1186/s12883-022-02898-6
work_keys_str_mv AT luhuanhuan immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT lisiyi immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT zhongxin immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT huangshuxuan immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT jiaoxue immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT heguoyong immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT jiangbingjian immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT liuyuping immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT gaozhili immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT weijinhong immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT linyushen immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT chenzhi immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment
AT liyanhua immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment